SCHEMBL940860

SCHEMBL940860

COc1cc2c(=O)oc3c(O)c(O)cc4c(=O)oc(c1OC)c2c34

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.84
CA1 P00915 3/20 0.84
CA7 P43166 3/20 0.84
CA9 Q16790 3/20 0.84
CA13 Q8N1Q1 3/20 0.84
RELA Q04206 1/20 0.84
KDM4E B2RXH2 2/20 0.70
MEN1 O00255 2/20 0.70
MAPT P10636 2/20 0.70
HPGD P15428 2/20 0.70
APEX1 P27695 2/20 0.70
RECQL P46063 2/20 0.70
BLM P54132 2/20 0.70
KMT2A Q03164 2/20 0.70
TDP1 Q9NUW8 2/20 0.70
ALDH1A1 P00352 1/20 0.70
PLK1 P53350 2/20 0.66
BACE1 P56817 2/20 0.66
PLK4 O00444 1/20 0.66
IKBKB O14920 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL941424 0.91 RELA (1.00) CA12CA1CA7CA9CA13
SCHEMBL30608638 0.91 RELA (1.00) CA12CA1CA7CA9CA13
SCHEMBL2355138 0.90 KDM4E (0.88) CA12CA1CA7CA9CA13
SCHEMBL38658338 0.89 CA12 (0.84) CA12CA1CA7CA9CA13
SCHEMBL3796697 0.88 CA12 (0.82) CA12CA1CA7CA9CA13
SCHEMBL941032 0.83 KDM4E (1.00) CA12CA1CA7CA9CA13
SCHEMBL29508368 0.83 KDM4E (1.00) CA12CA1CA7CA9CA13
SCHEMBL16401447 0.82 KDM4E (0.65) CA12CA1CA7CA9CA13
Ellagic Acid SCHEMBL28824363 0.81 KDM4E (0.92) CA12CA1CA7CA9CA13
Ellagic Acid SCHEMBL1645767 0.81 KDM4E (1.00) CA12CA1CA7CA9CA13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130324595-A1 C-GLUCOSIDIC ELLAGITANNIN COMPOUNDS FOR USE FOR ALTERING THE SUPRAMOLECULAR ARRANGEMENT OF ACTIN AND FOR THE TREATMENT OF OSTEOPOROSIS, CANCER, BACTERIAL INFECTION AND VIRAL INFECTION INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2013-12-05 US claimed
WO-2012113835-A1 C-GLUCOSIDIC ELLAGITANNIN COMPOUNDS FOR USE FOR ALTERING THE SUPRAMOLECULAR ARRANGEMENT OF ACTIN AND FOR THE TREATMENT OF OSTEOPOROSIS, CANCER, BACTERIAL INFECTION AND VIRAL INFECTION INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2012-08-30 WO claimed
CN-102485231-A Discocleidion sufescens Pax et Hoffm. extract, preparation method thereof and purpose thereof UNIV NANJING CHINESE MEDICINE 2012-06-06 CN claimed
JP-11322569-A None JP disclosed
JP-11292752-A None JP disclosed
JP-9202711-A None JP disclosed
WO-2024126540-A1 COSMETIC COMPOSITION COMPRISING NIACINAMIDE, A GINGER ROOT EXTRACT, A CARBOXYLIC ACRYLIC POLYMER, AN ACTIVE AGENT FOR COMBATING HAIR LOSS AND/OR AN ANTI-DANDRUFF ACTIVE AGENT L'OREAL (FR) 2024-06-20 WO disclosed
US-10772822-B2 Molecularly imprinted polymers and their use as antidandruff agents L'OREAL (FR) 2020-09-15 US disclosed
US-10555890-B2 Flexible solid cosmetic composition comprising anionic surfactants and solid particles, and cosmetic treatment process L'OREAL (FR) 2020-02-11 US disclosed
US-10548832-B2 Flexible solid cosmetic composition comprising anionic surfactants and polymer conditioning agents, and cosmetic treatment method L'OREAL (FR) 2020-02-04 US disclosed
US-20190125655-A1 MOLECULARLY IMPRINTED POLYMERS OF SOL-GEL TYPE AND THEIR USE AS ANTIDANDRUFF AGENT L'OREAL (FR) 2019-05-02 US disclosed
JP-2000247863-A COMPOSITION FOR EXTERNAL USE FOR SKIN LION CORP 2000-09-12 JP disclosed
US-6066312-A SKIN-LIGHTENING AND WHITENING EFFECTS LION CORPORATION (JP) 2000-05-23 US disclosed
JP-H11322569-A COMPOSITION FOR EXTERNAL USE FOR SKIN LION CORP 1999-11-24 JP disclosed
JP-H11292752-A BEAUTIFULLY WHITENING AGENT AND COMPOSITION FOR EXTERNAL USE FOR SKIN LION CORP 1999-10-26 JP disclosed
JP-H09202711-A BEAUTIFYING AND WHITENING AGENT AND EXTERNAL PREPARATION COMPOSITION LION CORP 1997-08-05 JP disclosed
US-5141741-A Calcium, barium, magnesium salt of ellagic acid LION CORPORATION (JP) 1992-08-25 US disclosed
EP-0294808-B1 AGENT FOR EXTERNAL APPLICATION AND USE THEREOF LION CORPORATION (JP) 1992-04-22 EP disclosed
US-5073545-A Cosmetic whitening or lightening of human skin LION CORPORATION (JP) 1991-12-17 US disclosed
EP-0294808-A1 Agent for external application and use thereof LION CORPORATION (JP) 1988-12-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10772822-B2 Molecularly imprinted polymers and their use as antidandruff agents DNMT1, POLR1C, ETF1 CA12 959/4885CA1 1695/4885CA7 1662/4885
US-10548832-B2 Flexible solid cosmetic composition comprising anionic surfactants and polymer conditioning agents, and cosmetic treatment method KRT18, CUTA, MUC1 CA12 376/4885CA1 1140/4885CA7 630/4885
US-10555890-B2 Flexible solid cosmetic composition comprising anionic surfactants and solid particles, and cosmetic treatment process CUTA, KRT18, KAT7 CA12 303/4885CA1 795/4885CA7 354/4885
US-20190125655-A1 MOLECULARLY IMPRINTED POLYMERS OF SOL-GEL TYPE AND THEIR USE AS ANTIDANDRUFF AGENT POF1B, PIK3C3, DNMT1 CA12 613/4885CA1 637/4885CA7 1366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.